Arcus Corp (RCUS) Long-Term Debt to Capital Ratio

Arcus Biosciences, Inc. - graphic logo of issuer RCUS

The market trend for Arcus Biosciences, Inc. (RCUS) analyzed on the GURU.Markets price chart, where the individual long-term debt indicator stands at 0.22, operates within the field of cancer immunotherapy. The company's authority is bolstered by collaborations with major pharmaceutical giants and recognition from the scientific community. The business is insulated from economic cycles, with its viability determined by liquidity levels. Growth potential is based on patents that enable the profitable global sale of its developments.

Long-Term Debt to Equity: Arcus Biosciences, Inc. (RCUS) for 07/04/2022 - 10/31/2026

Analytical breakdowns for Arcus Biosciences, Inc.

- market price and analyst price targets:
Market Price Arcus Biosciences Inc|RCUS - Price Target Chart
- market capitalization details:
Market Capitalization Arcus Biosciences, Inc.|RCUS - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Arcus Biosciences|RCUS - Company Book Value|Market-to-Book Ratio arcusbio.com|RCUS - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Arcus Biosciences, Inc.|RCUS - Long-Term Debt to Equity|Current Liabilities to Capital arcusbio.com|RCUS - Company Aggregate Debts|Debt to Net Assets Arcus Biosciences, Inc.|RCUS - Company Long-Term Liabilities|Short-Term Debt Arcus Biosciences|Intermediate Coverage Ratio arcusbio.com
- company profitability and valuation multiples indicators:
RCUS - Net Profit
Summary company analysis:RCUS - Arcus Biosciences Inc
Brand item of Arcus Bio

Aggressively retaining the R&D core and attracting clinicians requires stable funding, making the control of long-term liabilities critically important for Arcus Biosciences, Inc. (RCUS). The ratio of loans with a maturity of more than one year to equity measures financial leverage and solvency, allowing an investor to assess the risk of over-indebtedness through the structure of long-term debt relative to capital.

Competing companies

Long-Term Liabilities to Capital ImmunityBio Inc IBRX|Long-Term Debt to Equity Immunocore PLC (IMCR)|Janux Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital ZYME (Zymeworks Inc.)|TNGX - Long-Term Debt to Equity Ratio|IOVA - Long-Term Debt to Equity|Long-Term Liabilities to Capital Immatics NV|Xencor Corp (XNCR) - Long-Term Debt to Equity|CMPX (Compass Therapeutics Corp) - Long-Term Debt to Equity|Long-Term Debt to Equity Replimune Group, Inc.|Long-Term Liabilities to Capital lyell.com LYEL|Long-Term Debt to Capital IPHA|pyxisoncology.com (PYXS) - Long-Term Indebtedness to Equity|Compugen - Long-Term Debt to Equity Ratio|IO Biotech Inc. (IOBT) - Long-Term Liabilities to Capital|STRO: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient INKT (minktherapeutics.com)|HOWL: Long-Term Debt to Capital|IMMX - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ALX Oncology Holdings|Long-Term Debt to Equity Ratio cuebiopharma.com (CUE)|Long-Term Debt to Equity PDS Biotechnology (PDSB)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|MAIA Biotechnology, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Liminatus Pharma Inc. LIMN|LVTX - Long-Term Debt to Equity|NXTC (NextCure Corporation) - Long-Term Debt to Capital Ratio|leaptx.com (LPTX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Intensity Therapeutics, Inc. (INTS)|Long-Term Debt to Equity Ratio SNSE|TOVX - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio GRTS (Gritstone bio, Inc.)|Long-Term Loans to Capital Ratio KA|Long-Term Debt to Capital NEXI (NexImmune, Inc.)|Long-Term Debt to Capital Coefficient TSBX|Vaccinex - Long-Term Debt to Capital|Long-Term Liabilities to Capital Harpoon Therapeutics Inc